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Abstract 
Sphingosine kinases (SK1 and SK2) catalyse the conversion of sphingosine into sphingosine 1-phosphate and 
control fundamental cellular processes, including cell survival, proliferation, differentiation, migration and 
immune function. In this Review, we highlight recent breakthroughs in the structural and functional 
characterisation of SK1 and these are contextualized by analysis of crystal structures for closely related 
prokaryotic lipid kinases.  We identify a putative dimerisation interface and propose novel regulatory 
mechanisms governing structural plasticity induced by phosphorylation and interaction with phospholipids 
and proteins.  Our analysis suggests that the catalytic function and regulation of the enzymes might be 
dependent on conformational mobility and it provides a roadmap for future interrogation of SK1 function and 
its role in physiology and disease. 
 
Pivotal signalling roles of sphingosine kinases 
Sphingosine 1-phosphate (S1P) is an endogenous pleiotropic lipid mediator that regulates many 
physiological effects, including modulation of the vascular barrier integrity and tone, angiogenesis and 
trafficking of immune cells [1]. However, S1P also has a pathophysiological role in autoimmune dysfunction, 
inflammation, cancer and many other diseases [2-4]. S1P binds to and activates a family of five S1P-specific 
G protein-coupled receptors, S1P1-S1P5, following its release from cells through transporter proteins [5, 6]. A 
number of intracellular target proteins of S1P have also been identified, including histone deacetylases 
(HDAC1/2) and human telomerase reverse transcriptase (tHERT) [7, 8].  
Two distinct isoforms of sphingosine kinase (SK1 and SK2) catalyse the ATP-dependent phosphorylation of 
sphingosine (Sph) to produce S1P. These biochemically well-characterised enzymes are regulated in a spatial 
and temporal manner by post-translational modification and interaction with specific proteins and lipids 
(recently reviewed [9, 10]). SKs are part of a wider network of enzymes that inter-convert many 
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sphingolipids in response to environmental change and stimuli [11]. In general, the cellular effects of S1P 
(proliferation, migration, differentiation, survival) are largely opposed to those of ceramide (apoptosis, 
senescence, growth arrest etc.) and the concept of the ‘sphingolipid rheostat’ was proposed, whereby the 
inter-conversion of ceramide, via sphingosine, to intracellular S1P controls cellular fate [12, 13]. A more 
nuanced model incorporates both the receptor-mediated and intracellular effects of S1P [14, 15]. Moreover, 
ceramide exists as multiple molecular species that might have differing roles and act independently of S1P in 
a membrane- and target-specific manner [16], including supporting proliferation [17]. Nonetheless, the 
therapeutic potential of SK inhibitors (to raise apoptotic ceramide and reduce S1P formation) and S1P 
receptor antagonists has been intensively pursued, particularly within the context of cancer (recently 
reviewed by Santos & Lynch [18] and Kunkel et al. [5], respectively). Indeed, high SK1 expression is 
associated with poor prognosis and disease stage in a number of cancers [19, 20]. Similarly, in vitro evidence, 
disease models and patient data support a role for SK2 in cancer [21, 22]. Thus, oncology clinical trials for 
two low potency SK inhibitors are on-going or completed but not yet reported. The SK2 inhibitor, 
ABC294640, is in trials for pancreatic cancer, solid tumours and relapsed diffuse large B-cell lymphoma. The 
aim of this Review is to interrogate the available SK1 crystal structures with reference to those of related 
lipid kinases and so provide new insight into the structural features, binding sites, mechanism and regulation 
of SK1.  
Current structural models 
Two human SK genes, SPHK1 and SPHK2, give rise respectively to three SK1 splice variants (SK1a, SK1b. 
SK1c) and two confirmed SK2 variants (SK2a, SK2b), where the variants within each gene family differ in 
the length of the N-terminal sequence [14]. The first SK crystal structures were acquired with human SK1a 
[23]. In the absence of added ligands the protein crystallised as an asymmetric unit comprising three 
molecules of SK1 (PDB: 3VZB). A region of J-shaped electron density in two of the protein molecules 
suggested the presence of adventitious sphingoid base, with Sph providing the best fit for this feature; the 
third molecule was unliganded and taken to represent the protein in its apo-state. A structure (3VZC) was 
also obtained with crystals grown in the presence of an inhibitor, 4-((4-(4-chlorophenyl)thiazol-2-
yl)amino)phenol (SKI-II, also known as SKi), targeted to the Sph binding site. The nucleotide binding site 
was also defined in a third structure (3VZD) following co-crystallisation with both SKI-II and ADP. Two 
subsequent SK1 co-crystal structures (4L02, 4V24) with potent sphingosine-competitive inhibitors have 
provided additional details on the interaction of ligands in the Sph binding site [24, 25]. Crystal structures for 
SK2 have yet to emerge and thus discussion herein is focused primarily on SK1. 
SK1 overall structure and relation to DAGK_cat family proteins 
SK1 has a two-domain architecture (Figure 1, Key Figure) that comprises an N-terminal domain (NTD) with 
a binding site for the nucleotide and a C-terminal domain (CTD) hosting the Sph binding site. The catalytic 
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centre is located in a cleft formed at the inter-domain junction. The NTD is composed of six ȕ-strands (ȕ1-ȕ5 
and ȕ17) and six Į-helices (Į1-Į6) organised in an Į/ȕ/Į sandwich. Its core is provided by a 4-stranded ȕ-
sheet, ordered as ȕ2-ȕ1-ȕ3-ȕ4, with the edge of ȕ2 exposed on the outside surface distal to the CTD. Towards 
the catalytic cleft the sheet is extended by a fifth strand (ȕ5); the C-terminal ȕ17 strand, inserted between ȕ5 
and ȕ4, then completes a twisted 6-stranded sheet and serves to zip the two domains together. The CTD 
contains 11 ȕ-strands (ȕ6-ȕ16) that are organised as a two-layer ȕ-sandwich. Three extended loops between 
strands ȕ8-ȕ9, ȕ10-ȕ11 and ȕ11-ȕ12 pack across one face to generate the Sph binding site. The sequences are 
designated herein ‘lipid binding loop 1-3’ (LBL-1 to LBL-3) respectively. LBL-1 folds with two reverse-
paired KHOLFHV Į-Į such that the inter-helix connection is orientated into the catalytic cleft. The second 
loop, LBL-2, which is shorter and lacks secondary structure, also interfaces with the NTD at the catalytic 
cleft. LBL-3 folds without making direct contact with the NTD as an additional helix (Į9), running 
DQWLSDUDOOHODORQJĮ8. The lipid binding site is located between the helix bundle Į-Įand its interface with 
the CTD ȕ-sandwich. The reverse face of the ȕ-sandwich is occupied by a single regulatory loop (‘R-loop’) 
extension between strands-ȕ9/ȕ10 and hosts phosphorylation sites in both SK1 and SK2 [26, 27].  
Phylogramatically, SK1 and SK2 are grouped with mammalian diacylglycerol (DAG) kinase enzymes 
(DGKs) [28], other eukaryotic lipid kinases [29, 30] and prokaryotic enzymes of the bacterial DgkB class 
[31] into the DAGK_cat family (see Glossary). The mammalian DGKs are multi-domain containing 
proteins, but as yet no crystal structures are available for the catalytic domain of these enzymes or for other 
eukaryotic lipid kinases to facilitate comparative structure-function analysis with SK1. By contrast, nine 
crystal structures have become available for prokaryotic DAGK_cat relatives. The first of these were 
obtained for the YegS protein from Escherichia coli (2BON, 2JGR) [32] and its orthologue from Salmonella 
typhimurium (2P1R) [33]. DAG is not a substrate for YegS, and in vitro studies suggest that it may catalyse 
phosphorylation of phosphatidyl glycerol [32]. The first bona fide DGK to be structurally defined was the 
DgkB protein from Staphylococcus aureus [34]; structures obtained with and without bound ADP (2QV7, 
2QVL) provided initial insights regarding organisation of the nucleotide binding site in DAGK_cat proteins. 
Three crystal structures for a putative DGK from Bacillus anthracis subsequently emerged (3S40, 3T5P, 
4WRR) and one structure for a putative DGK from Enterococcus faecalis (4WER) [http://www.rcsb.org]. 
AMP is defined in the nucleotide binding site of the latter, but none of these structures are complexed with 
lipid substrates. All of the proteins exhibit a similar NTD fold and CTD core ȕ-sandwich, with the two 
domains connected by a pair of long antiparallel strands that characteristically cross over one another at the 
inter-domain junction. These twisted inter-domain strands in SK1 correspond to ȕ5+ȕ6 in the outward (NTD-
to-CTD) leg and ȕ16+ȕ17 in the return leg. In many DAGK_cat proteins an aspartic acid at the cross-over 
point contributes to a regulatory metal ion binding site [32-34]. This is absent in SK1, but, based on sequence 
analysis (Figure S1), might potentially be retained in SK2. Collectively the prokaryotic DAGK_cat structures 
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exhibit strong conservation in the key structural motifs that bind ATP, but differ from SK1 in the structure of 
the CTD extended loops. 
 
Substrate binding sites 
The nucleotide binding site in SK1 (Figure 1) is highly homologous with the corresponding site in the 
prokaroytic DAGK_cat proteins; key interaction motifs are defined on the SK1 sequence presented in the 
supplementary material (Figure S1). The adenine is inserted into a groove between the ȕ1-Į1 and ȕ2-Į2 loops, 
making contacts with residues 22-NPR-24 (motif-1) and 54-TERR-57 (motif-2). Motif-3 (79-SGDGLMHE-
86), a DAGK_cat signature sequence encompassing the ȕ3-Į3 loop [34], provides key contacts for the Į-
phosphate of the nucleotide and is often referred to as the ‘P-loop’. The ȕ-phosphate is engaged by motif-4 
(111-GSGNAL-116), another DAGK_cat signature sequence. Frequently in the form of GTXND in the wider 
family, this motif is referred to as the ‘T-loop’ [34]. The catalytic Mg2+ ion, coordinated to the phosphates, is 
bound by another conserved element of DAGK_cat proteins, a DGE sequence (motif-5), through the 
carboxylate of Glu343 and backbone carbonyl of Asp341. The ȕ-phosphate is also engaged by Arg185 and 
Arg191 from LBL-1, although the position of Arg191 is such that it might be reconfigured for binding the 
$73Ȗ-phosphate and incipient S1P product arising from catalytic turnover. 
Consistent with their action on distinct substrates, the DAGK_cat proteins that have been structurally 
characterised to date differ significantly in the structure of their lipid binding regions, especially LBL-1 and 
LBL-2 (Figure S2). In the case of SK1 Sph is accommodated within a curved tube, the ‘J-channel’, and 
makes extensive surface contact with the protein, involving hydrophobic residues in the three lipid binding 
loops and across one face of the CTD ȕ-sandwich core. Key residues in the binding site are largely conserved 
between SK1 and SK2. Differences occur at four sites, with two of these, Ile174/Met272 (Val304/Leu517 in 
SK2), located in the throat of the J-channel and a third, Phe288 (Cys533 in SK2), at its toe. The fourth 
distinguishing residue, Ala339 (Thr584 in SK2), is linked through a networked water to the Sph head group, 
which is highly organised through additional hydrogen bonds to Asp178/Ser168 (Figure 1). The Sph-1-OH is 
positioned in loose contact with P-loop Asp81, which simultaneously caps the T-loop with two hydrogen 
bonds at the N-terminus of helix-Į. The Sph-3-OH engages Asp178 on LBL-1 as a key anchor point (Figure 
1). Co-crystal structures have been obtained with three inhibitors that all exploit J-channel occupancy (Figure 
S3). Two of these, Amgen-1V2 and PF-543 [24, 25], possess Sph-mimetic head groups and target Asp178 
with a hydroxymethyl group in place of the Sph-3-OH. In the absence of a suitable hydroxylated ligand, as in 
the SKI-II-bound and apo SK1 crystal structures, the Sph-3-OH site is occupied by a surrogate water 
molecule, suggesting that the lipid head group interaction region involving Asp178 is highly preorganised for 
substrate binding in SK1. 
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Catalytic mechanism 
At some point during catalytic turnover the phosphoacceptor hydroxyl of Sph must undergo deprotonation. 
P-loop residue Asp81, which is proximal to the hydroxyl in the Sph-bound crystal structure (Figure 1), has 
been assigned as the general base responsible for this [23]. A surprising feature, however, is the involvement 
of Asp81 as a doubly hydrogen bonded cap for helix-Į, which could potentially reduce its ability to function 
as a base. Nevertheless an available hydrogen bond site on the Asp81 carboxylate remains, and access to this 
site is evinced in the Sph-bound SK1 crystal structure. Asp81 is therefore implicated in the catalytic 
mechanism (Figure 2).  
Collectively, the SK1 crystal structures reveal FRQVLGHUDEOHSODVWLFLW\ LQ WKHȕ-phosphate binding T-loop, a 
feature that is also evident in the available prokaryotic DAGK_cat crystal structures, where it is associated 
with conformational switching in the capping mode of the Asp81-cognate residue. Thus, the B. anthracis 
DGK structures reveal, in one case (3S40), a doubly-capped state for the aspartate and, in two other cases 
(3T5P, 4WRR), a singly-capped state in which only one of the aspartate oxygens engages the T-loop whilst 
the second is lifted towards the site that would be occupied by the Sph-1-OH in SK1. Movement in the T-
loop, dependent on nucleotide occupancy, may therefore play an important role in the mechanism, and Asp81 
might possibly switch to a singly-capped T-loop mode with bound ATP, allowing optimisation of both 
presentation and basicity at the point of catalytic turnover. It is also conceivable that plasticity in the T-loop 
allows the key H-donor centres for the ȕ-phosphate to track separation of ADP from the Ȗ-phosphate during 
the reaction pathway from substrates to products. This is suggested by remarkable differences in T-loop 
backbone NH trajectory that distinguish the ADP-bound and nucleotide-free SK1 crystal structures. 
Lipid substrate access 
In general the mechanisms whereby lipid kinases locate and act on their substrates are poorly understood. 
Phosphorylation may occur with the lipid still anchored in a membrane in some instances [35].  However, for 
SK1 the complete enclosure of Sph within the CTD suggests a full lipid extraction-encapsulation action. 
Only a narrow entry to the J-channel exists, where it opens to the ATP binding site, and access through this 
point would require Sph to tunnel tail first past a guard of polar residues.  A more reasonable mode of 
substrate entry would involve opening and closure of helices-Į/%/-1), which form a flap over the Sph 
binding site. The likelihood of such LBL-1 movement is suggested by the other DAGK_cat crystal structures, 
such as the Enterococcus '*. VWUXFWXUH :(5 ZKHUH WKH Į-cognate region is disordered but a helix 
FRUUHVSRQGLQJWRĮLVZHOOGHILQHG,QWKLVFDVHWKHlatter helix is flipped outwards to expose both its own 
LQQHUK\GURSKRELFVXUIDFHDQGWKDWRIWKHȕ-sandwich core (Figure 3). The helix is trapped in this open state 
by crystal lattice packing unique to this particular structure, but its observed position highlights the 
plausibility of an open-FORVHPRYHPHQW LQ WKHĮ µOLSLG OLG¶KHOLFHV&RQFHLYDEO\ WKH FDWDO\WLF DFWLRQRI
SKs may thus function by transient opening of LBL-1 and presentation of head group-interacting residues to 
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facilitate substrate recognition at the membrane interface, with subsequent extraction accompanied by closure 
of LBL-1 to encapsulate the lipid substrate. 
 
Oligomerisation of SK1 
Inspection of the available prokaryotic DAGK_cat crystal structures reveals a common pattern of dimeric 
assembly through NTD-NTD engagement (Figure 3). The only exception to this pattern is the 
aforementioned Enterococcus DGK crystal structure (4WER), where interlocking of the CTD LBL-1 dictates 
the solid state assembly. Some diversity is seen in the NTD-NTD dimerisation interfacial sequences, 
molecular interactions and subunit orientation, but in all cases the dimer assembly features some degree of 
annealing along the exposeG ȕ VWUDQGV RI WKH SURWRPHUV This is augmented by additional interactions 
involving flanking helices-ĮĮDQGtheir connecting loops. Similar inspection of the SK1 structures reveals 
that in each case all of the constituent protein molecules are paired through an NTD-NTD interface with C2-
symmetry (Figure 3), suggesting that the enzyme may adopt a dimeric quaternary structure. Although 
oligomerisation has yet to be reported in intact non-transfected in vivo systems, the capacity of SK1 to 
dimerise is consistent with the results of immunoprecipitation experiments with expressed differentially 
tagged SK1 constructs in cells [36, 37]. Interface-contributory residues (identified in Figure S1) are not fully 
conserved between SK1 and SK2. Thus, the NTD-NTD contact for SK2 will differ from that in the SK1, if 
indeed SK2 dimerises through such an interface.  
The ȕ2-Į2 loop (54-TERR-57), which contributes to the ATP binding site in SK1, is directly involved in 
cross-subunit interactions at the putative dimer interface through the side chains of Glu55/Arg56. However, 
comparison of the SK1 crystal structures reveals some degree of plasticity in this loop. Thus, one (‘loop-out’) 
conformation has the backbone folded towards the dimerisation interface cleft. A second (‘loop-in’) 
conformation has the backbone folded slightly into the ATP binding site. Conformational adjustment may 
therefore potentially influence nucleotide binding. Intriguingly an asymmetric mixed loop-out/loop-in dimer 
state is observed in the 3VZB crystal structure for a pairing between Sph-complexed and apo-SK1 protein 
molecules. Moreover, in the apo-SK1 molecule, the LBL-1 inter-helix residues exhibit some positional 
movement (up to 6Å) compared to SK1 molecules with ligand occupancy (Sph or inhibitor) in the CTD. This 
is accompanied by establishment of an inter-domain hydrogen bond between Arg57 on the ȕ-Į loop and 
the backbone of Leu344 immediately adjacent to the DGE-motif. These observations might suggest a model 
where the ȕ-Į loop conformation may be influenced both by the presence or absence of ligand in the lipid 
binding site and by a cross-subunit relay via the dimerisation interface within an oligomeric assembly [37, 
38].  
Regulatory control 
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Subcellular localisation of SK1 and SK2 critically underpins their biochemical roles (reviewed elsewhere 
[39-43]) and dictates transformation of normal cells into cancer cells [44]. In unstimulated cells SK1 is a 
predominantly cytosolic enzyme, but stimulation with a range of agonists can elicit both upregulation of SK1 
catalytic activity [45-55] and translocation to the plasma membrane [26, 44, 56-59]. One such stimulatory 
pathway, that has provided a model for understanding translocation of SK1 to the plasma membrane (PM), is 
the response to phorbol myristate acetate (PMA) [53, 57]. This leads ultimately to phosphorylation of SK1 on 
Ser225, which regulates PM-targeting and enhanced SK1 activity [26]. The phosphorylation is mediated by 
extracellular signal-regulated kinase (ERK1/2) and is reversed by the action of protein phosphatase 2 (PP2A) 
[60]. Interactions with both phosphatidylserine (PS) [61, 62] and phosphatidic acid (PA) [63] have also been 
implicated in the activation/localisation of SK1 at the PM and endoplasmic reticulum (ER)/Golgi-apparatus. 
Indeed, it has been proposed that engagement of PS could involve specific recognition of the lipid head 
group at a site exposed in the protein upon phosphorylation of Ser225 [62]. Thr54 and Asn89 have 
tentatively been implicated as contributory residues to a PS-binding site, as both were shown to be important 
for SK1 binding to PS-derived vesicles and (in cell culture) also to the PM [62, 64].  
Ser225 occupies a prominently solvent-exposed location in the R-loop, packed on the reverse side of the 
CTD core ȕ-sandwich to the lipid binding site. The tip of the R-loop (231-QGP-234) packs against NTD 
helices-Į3/4 (94-RPDW-97) and is maintained in this position by insertion of R-loop Asp235 into a pocket 
on the ȕ-sandwich surface lined by His156/Arg162/His355 (Figure 4). Ser225 appears ideally poised to 
displace Asp235 from this pocket upon phosphorylation, and this would in turn displace the R-loop from its 
NTD engagement, potentially eliciting structural transition in helices-Į3/4. Clues as to the possible structural 
impact on helices-Į3/4 lie in the crystal structures of the Staphylococcus DgkB, which contains a helix-Į3 
sequence (76-NGIAEKPNR-84) homologous to that of SK1 (89-NGLMERPDW-97) but lacks the R-loop. 
The glutamate in this sequence engages basic residues in the CTD, whereas in SK1 it is folded back along the 
Į3-axis to pin down the side chains of Arg61/Arg65 from the adjacent helix-Į2. In principle, R-loop 
displacement could allow conformational relaxation in the SK1-ERPD sequence, and a direct mapping onto 
the cognate DgkB-EKPN motif would release Arg61/Arg65, opening a potential binding site adjacent to 
Asn89 (one of the residues previously implicated in PS binding). Alternatively, as the SK1 crystal structures 
show that Asn89 contributes a cross-domain double H-bond contact, the importance of Asn89 may lie not in 
direct contact with PS, but in the maintenance of appropriate NTD-CTD spacing to facilitate the postulated 
conformational switching of Glu93. 
Thr54 adopts two distinct rotameric states in the SK1 crystal structures. In one state the hydroxyl is 
orientated towards the ATP binding site, as an adenine contact point, and in the second it is reversed to cap 
helix-Į. This conformational switching is allied to plasticity in the ȕ-Į loop that affects the presentation 
of proximal residues defining the surface of the putative dimerisation interface cleft (His59/Glu55/Arg56) as 
well as Arg57 on the ȕ-Į loop itself. Thus, Thr54 may play a key role in orchestrating ȕ-Į loop structure 
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to facilitate PS binding, potentially at the proposed dimerisation interface cleft. Definitive clarification of the 
involvement of Thr54/Asn89 in PS binding requires further structural investigation, but reconfiguration of 
the R-loop upon phosphorylation of Ser225 may influence the conformation of the Thr54-containing ȕ-Į 
loop by controlling the engagement of Į-Glu93 with Į-Arg61/Arg65 as discussed above. Moreover, a 
strong cluster of arginines in/near to the putative dimerisation cleft (residues-16/24/56/57/61/65) could be 
consistent with this region of the protein acting as a contact surface for anionic phospholipids. 
Although maintenance of residence at the PM requires interaction with lipids, active translocation of SK1 
may be influenced by other factors, with preliminary work suggesting that calmodulin binding might be 
important for membrane targeting [56, 65]. Further investigation refined this understanding and identified 
Calcium- and Integrin-Binding Protein (CIB1) as the active, calcium-sensing partner that mediates 
translocation of SK1 [66]. The CIB1 binding site was localised to the sequence now defined as helix-Į8 from 
the crystal structures (Figure 4), within which combined F197A/L198Q substitution was shown to ablate 
CIB1 binding and SK1 translocation. However, the same exposed LBL-1 hydrophobic surface has recently 
been implicated in direct curvature-sensitive binding of SK1 to negatively charged membranes [67].  
Significantly, the exposed LBL-1 surface of both protomers is aligned along the same edge of the putative 
SK1 dimer. Moreover, an electrostatic potential surface map of the dimer reveals a region of high positive 
charge density over a concave surface separating the two LBL-1 sites (Figure 5). Docking of this surface to a 
convex negatively charged membrane interface might reasonably allow simultaneous embedding of both 
LBL-1 sites into the membrane to facilitate substrate extraction by the gating mechanism proposed in Figure 
3. The postulated dimerisation of SK1 may therefore have direct bearing on curvature-sensitive membrane 
recruitment of the enzyme, which has been shown to be important in endocytosis [67]. 
The C-terminal sequence of SK1 also plays an important regulatory role, and truncation after residue 363 
renders SK1a constitutively active and insensitive to stimulation by PMA [68].  This 21-residue C-terminal 
deletion also enhances localisation at PS-containing lipid raft microdomains without requirement for 
phosphorylation of Ser225. Extension by four additional residues (364-367) restores the lower basal activity 
levels of wild-type SK1a, but, remarkably, in a manner that is independent of residue identity. In the 
available crystal structures Gly364 is located immediately adjacent to the exposed C-terminus of the short 
helix-ĮDWWKHRSSosite end to the T-loop and catalytic centre. These crystal structures were acquired with 
proteins truncated after Gly364, but it is clear that the peptide backbone over residues 364-367 would be 
well-positioned to act as a C-terminal cap for helix-Į (Figure 6). Moreover, given the plasticity of the T-
loop and its relevance to the catalytic mechanism, any leverage exerted on helix-Į E\ VXFK D FDS PLJKW
plausibly be relayed into the catalytic centre to modulate activity. Enhanced membrane targeting of the C-
terminally truncated SK1a protein might suggest that displacement of the C-terminal sequence also unmasks 
the postulated anionic phospholipid binding site or frees access to the membrane binding surface of the 
enzyme, and, therefore, that the structural transition arising from R-loop phosphorylation might serve to 
9 
 
modulate the interaction of the C-terminal sequence with the core catalytic domain. Sequestration of the SK1 
C-terminal sequence by partner proteins might thus conceivably unmask the membrane-interacting 
determinants of SK1 to facilitate membrane recruitment without phosphorylation of Ser225. This could 
perhaps explain a finding that Gq-coupled M3 muscarinic receptor signalling induces translocation of SK1 to 
the PM in a manner that is independent of Ser225 phosphorylation and changes in [Ca2+]i [69]. No SK1-
interacting protein partner was identified in that study, but some protein associations with the SK1 C-
terminus have been established (see Figure 6). Interestingly, the position of Gly364 is such that the C-
terminal sequence would project sideways and clear of the membrane surface from an SK1 dimer docked, as 
proposed above, through the interfacial LBL-1 motifs and positively charged groove. Protein binding to the 
SK1 C-terminus may, then, be feasible for such a dimer whilst actively engaged at a membrane interface. 
Whilst a structural basis for regulatory control of SK1 activity and targeting has yet to be firmly established, 
interaction with anionic phospholipids appears to be important, and we propose that the membrane curvature-
sensing property of SK1 may be related to a dimeric architecture. Membrane recruitment is clearly 
influenced by the phosphorylation status of the R-loop, but the evidence above suggests that the C-terminal 
sequence also critically affects membrane binding and catalytic activity. SK1 crystal structures with the intact 
C-terminus are currently not available, but an important possibility that should be considered is whether 
structural transition induced by phosphorylation modulates interaction of the C-terminus with the core 
catalytic domain to disclose the membrane-binding determinants of SK1. 
Concluding remarks 
In this Review we have provided an explanation of the molecular and structural organisation of SK1 as it 
relates to catalysis, regulatory control and the role of the enzyme in cell biology. Several new structure-
function hypotheses are presented that raise key questions and provide direction for future investigation (see 
Outstanding Questions). An understanding of the dynamic changes in SK1 structure, which underpin its 
biological action in health and disease, will provide a basis for multiple approaches to target this enzyme 
with small molecule modulators that include both allosteric [37] and orthosteric-directed compounds.  
Glossary 
Calcium- and integrin-binding protein (CIB1): a ubiquitous 191-residue protein comprising globular 
N-terminal and C-terminal domains, each composed of two EF-hands separated by flexible linker. The 
two C-terminal EF-hands bind Ca2+ ions with affinities just above basal Ca2+ concentration levels. 
Calcium binding elicits structural transition that exposes a membrane-targeting N-terminal myristoyl 
group and as well a groove for partner protein interaction, the latter by unfolding of a C-terminal helix. 
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DAGK_cat family (Pfam 00781): a protein family that encompasses 10 mammalian diacylglycerol 
kinases (DGKs) together with other eukaryotic lipid kinases [ceramide kinase (CerK), a multi-substrate 
lipid kinase (MULK) and SKs]. Bacterial DGKs fall into two distinct classes: a group of soluble DGK 
proteins, denoted DgkB, that are expressed by Gram-positive organisms and belong to the DAGK_cat 
family; and an unrelated group of integral membrane proteins, DgkA (Pfam 01219), expressed in 
Gram-negative organisms. 
 
Figure 1 caption (full-width figure) (REVIEW KEY FIGURE) 
Figure 1, Key Figure. Tertiary structure and substrate binding site detail for SK1. Centre: Sph•SK1 co-
crystal structure (3VZB chain A) with Sph (blue surface) encapsulated in the CTD; Mg•ADP (green 
sphere/pink surface) is shown superimposed from a separate SK1 co-crystal (3VZD chain C) [23]. Labelled 
secondary structure features correspond to the sequence mapping (Figure S1); key motifs and loops are 
coloured coded (see Ribbon Key). The crystal structure was acquired with a protein construct encompassing 
residues 9-364 of hSK1a; this construct exhibited comparable catalytic activity to the full-length enzyme of 
384 residues (which failed to crystallise satisfactorily). The regulatory R-loop is fully ordered for this chain 
but exhibits some disorder in other chains and crystal structures, particularly in its C-terminal half including 
the ERK1/2 phosphorylation site (Ser225, circled). None of the available SK1 structures encompass the C-
terminal 20-residue sequence that facilitates binding of PP2A (for dephosphorylation of Ser225) and 
mediates additional regulatory control [60, 68]. Top left and right: Binding site detail and residue interaction 
map for Sph (yellow stick) showing the curved fit of the lipid tail to the J-channel and highly organised polar 
interaction network surrounding the head group. SK2 differs (Figure S1) in binding site residues 
corresponding to I174, M272 and F288 (red surface) and A339. A structural water (W1), conserved in all 
SK1 crystal structures, and D178 engage the Sph-3-OH. The Sph-1-OH binds in two states, loosely (3.4 Å 
contacts) to L268 and P-loop residue D81 (catalytic base). Bottom right and left: Nucleotide binding site 
detail and residue interaction map showing the Į- DQGȕ-phosphates engaged respectively by P-loop and T-
loop. 
Figure 2 caption (side-captioned figure) 
Figure 2. Catalytic mechanism and protein plasticity at the catalytic centre. A mechanistic formulation for 
substrate phosphorylation (panel A) involves polarisation of the phosphoacceptor hydroxyl through H-
bonded contact to D81 in the enzyme-substrate complex; tKH HQVXLQJ QXFOHRSKLOLF DWWDFN RQ WKH $73 Ȗ-
phosphate might then proceed with concomitant full deprotonation of the substrate hydroxyl by D81 as the 
putative catalytic base [23]. R185 and R191 both hydrogen bond to the nucleotide’s ȕ-phosphate in the 
Mg•ADP co-crystal structure (Figure 1), but with suboptimal hydrogen bond trajectory due to proximal 
11 
 
congestion of the juxtaposed guanidinium moieties. This suggests that R191 may preferentially ELQGWKHȖ-
phosphate in complex with ATP and thence to the incipient S1P phosphate during catalytic turnover. 
R185/R191 and residues of the T-loop exhibit significant conformational mobility across the available SK1 
crystal structures. T-loop plasticity (panel B) alters backbone NH trajectory and may allow the T-loop to 
WUDFN VHSDUDWLRQRI $'3 IURP WKH Ȗ-phosphate during the reaction course. In the wider DAGK_cat family 
crystal structures plasticity encompasses conformational switching of the D81-cognate residue between 
single and double H-bond capping of the T-loop, as illustrated for the B. anthracis DGK (panel C). Binding 
of ATP in SK1 may thus induce T-loop movement in SK1 to tighten the Sph-1-OH/D81 H-bond, potentially 
with D81 in a singly-capped state.  
Figure 3 caption (side-captioned figure) 
Figure 3. Lipid substrate entry and quaternary structure hypotheses. The available prokaroyotic DAGK_cat 
family structures reveal a general pattern wherein LBL-1 (cyan ribbon) is characterised by helical secondary 
VWUXFWXUH HOHPHQWV FRQQHFWHG WR WKH FRUH ȕ-sandwich by flexible linkers (often disordered). In the 
Enterococcus DGK structure (top), the sequence corresponding tR Į LQ 6. LV GLVRUGHUHG ZKLOVW WKH Į-
cognate helix is flipped open, exposing the hydrophobic interior to accommodate the same helix (cyan mesh) 
from an adjacent protein molecule in the crystal lattice. This suggests that the DAGK_cat LBL-1 loop is 
conformationally mobile and provides a plausible mechanism for Sph entry in SK1 (centre). Analogous 
movement (black arrows) in helices-ĮĮRI6.PD\SURYLGHDJDWLQJPHFKDQLVPIRUHQWU\DQGH[LWRI6SK
and S1P (blue and red arrows respectively). With the exception of the Enterococcus DGK crystal structure, 
all of the other prokaryotic DAGK_cat crystal structures reveal a common pattern of dimeric assembly 
through NTD-NTD engagement, illustrated for the Staphylococcus DgkB structure (bottom). An analogous 
C2-symmetric dimer assembly is observed in all five of the currently available SK1 crystal structures, which 
exhibit different crystallographic space groups, and may represent a bona fide biological oligomer. Here the 
putative SK1 dimer (centre) is viewed along its C2-symmetry axis; interfacial residues are marked (red font) 
on the sequence in Figure S1. Some variance in subunit relative rotation is seen across the DAGK_cat 
dimers; the Staphylococcus DgkB structure (bottom) is presented with the left hand subunit aligned to the left 
hand SK1 protomer directly above.  
Figure 4 caption (full-width figure) 
Figure 4. SK1 regulatory processes and allied mechanistic hypotheses. Membrane-targeting of SK1 is 
influenced by phosphorylation of S225 and interaction with CIB1. The structure of SK1 is shown (centre) 
orientated to highlight the R-loop and position of S225, colour coding as keyed in Figure 1. The R-loop tip 
(231-QGP-233) makes inter-domain contact with residues (93-ERPDW-97) at the junction of helices-Į3Į4, 
with the loop conformation controlled by insertion of D235 into a base-lined pocket (H156/R162/H355), 
detailed in inset A. PhosphoS225 may displace D235, with reconfiguration of the loop position (black 
arrows) and thence reconfiguration of the 93-ERPDW-97 residues as detailed in inset B, where the 
superimposed ribbon (magenta) corresponds to SK1 89-NGLMERPDW-97 mapped onto the cognate motif 
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(76-NGIAEKPNR-84) of the Staphylococcus DgkB protein (2QV7). Conformational repositioning of E93 
(red arrow) could influence the orientation of Į2-R61/R65, thus affecting the structure proximal to N89 
or/and (via the ȕ-Į ORRS 7 WKHVH UHVLGXHV KDYLQJ EHHQ LPSOLFDWHG LQ WDUJHWLQJ WR 36-rich membrane 
domains [62, 64]. F197/L198 (cyan stick) on helix-Į8 are implicated in binding to CIB1. Potentially this 
might involve opening of LBL-1, as postulated for substrate access in Figure 3, freeing helix-Į8 to engage 
the CIB1 protein interaction groove, as in inset C. Binding to CIB1, by analogy to its precedented protein 
associations [70-72], may require unfolding of the CIB1 C-terminal helix (purple ribbon) from the protein 
interaction groove. Conceivably, if SK1 translocation proceeds in an LBL-1 ‘loop-open’ state, the displaced 
CIB1 helix might engage SK1 in a manner similar to that illustrated with the Enterococcus DGK helix 
insertion in Figure 3. 
 
Figure 5 caption (full-width figure) 
Figure 5. SK1 membrane engagement hypothesis. (A) Dimerisation of SK1 according to the 
crystallographically observed state results in presentation of the two LBL-1 lipid gate loops (cyan ribbon) on 
the same face of the cylindrical assembly. LBL-1 has recently been implicated [67] as a site for direct 
curvature-sensitive binding to negatively charged membranes, with mutagenic replacement of surface-
exposed hydrophobic residues (F197/L198, cyan stick, marked) ablating membrane targeting. The location of 
T54, another residue shown [62, 64] to be important for binding to negatively charged membranes is marked 
(spheres). (B) Application of a qualitative electrostatic potential surface to the SK1 dimer, viewed from the 
same perspective as panel A, shows a concave positively charged surface region (green box) separating the 
hydrophobic LBL-1 islands (cyan circles) across the dimer interface. (C) SK1 targets narrow tubular 
membrane invaginations of average diameter 23 nm in an experimental model of early endocytic 
intermediates [67]; here an approximate scale view is shown with the SK1 dimer orientated to a convex 
surface corresponding to the cross section of these tubular invaginations (orange ring, membrane depth not to 
scale). The view perspective has SK1 orientated at right angles to that in panel A and with the surface groove 
aligned along the tubule axis for hypothesised interaction with anionic phospholipids (circled –ve charge). 
Docking in this manner might reasonably allow simultaneous embedding of both LBL-1 sites into the 
membrane to facilitate substrate extraction by the postulated gating mechanism (black arrows). 
Figure 6 caption (side-captioned figure) 
Figure 6. Regulatory and targeting hypotheses for the SK1 C-terminal sequence. (A) Available SK1 crystal 
structures derive from protein constructs truncated at G364 (red spheres); G364 is juxtaposed to the C-
terminal end of helix-ĮZKLFKDOVRKRVWVWKH7-loop (marked) at the catalytic centre. (B) The C-terminal tail 
sequence of 21 residues (365-CVEPPPSWKPQQMPPPEEPL-384) is missing from available structures but is 
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known to host protein binding sites: residues 379-PPEE-382 bind tumour necrosis factor receptor-associated 
factor 2 (TRAF2), a component in the multi-protein assembly resulting from engagement of the tumour 
necrosis factor (TNF) receptor [73], whilst residues 368-384 have been implicated in binding protein 
phosphatase 2 (PP2A) [60]. Membrane binding of the SK1 putative dimer, according to the hypothesised 
mode of Figure 5, would position G364 such that the missing C-terminal sequence of the two protomers 
(dotted red lines) could extend to engage in protein associations. In the absence of bound proteins the tail 
sequences may potentially fold to obstruct binding to membrane interfaces, thereby conferring cytosolic 
distribution; C-terminal protein association may then unmask membrane interaction determinants in SK1. 
Alternatively, structural transition in the R-loop elicited by phosphorylation of S225 may also promote 
release of the C-terminal tail to facilitate membrane targeting. (C) An expansion (orientated as in panel B) 
suggests that the backbone of residues 364-367 may cap helix-Į 'HOHWLRQ RI WKH &-terminal sequence 
activates SK1 [68], probably by altering leverage on the T-loop.  
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 Figure S1. SK sequence alignment, secondary structure and key feature map. Multiple N-terminal splice variants have 
been identified from both mammalian SK genes [S1]; the alignment here uses SK1a and SK2a, UniProt entries 
Q9NYA1-1 and Q9NRA0-1 respectively [http://www.uniprot.org/]. Alignments with other DAGK_cat proteins have 
been published elsewhere [S2, S3]. Five regions (C1-C5) that are highly conserved in SK1 and SK2 across species are 
marked (orange underline) [S4]. Key structural features (motifs-1 to -5) that bind the nucleotide and/or catalytic metal 
ion are also highlighted (olive boxes, with white numbering to designate residue position). Extended loops that 
contribute to Sph binding (LBL-1 to LBL-3) and regulatory control (R-loop) are identified (violet boxes). Sph-interacting 
aspartates D81/D178 are identified (SK2 numbers in parenthesis). Structurally characterised prokaryotic DAGK_cat 
relatives lack the R-loop but exhibit a non-catalytic metal binding site (NCM, blue box) involving an aspartate, 
corresponding to Asn151 in SK1, at the centre of a twisted inter-domain strand pair. The ion is bound by an additional 
encircling loop, corresponding to 280-RCAAGV-285 in SK1, through backbone carbonyl coordination from residues in 
the P1/P6-positions and by an aspartate in the P4-position. Although the NCM-loop is retained in SK1, neither of the 
essential aspartates is conserved. By contrast, SK2 possesses both aspartates (Asp281/Asp527) and a loop sequence 
(524-RFDDGL-529) commensurate with metal-binding capacity. The role of the DAGK_cat NCM-site is not fully 
understood, but has been implicated in a Ca2+-ĂĐƚŝǀĂƚŝŽŶŵĞĐŚĂŶŝƐŵŝŶzĞŐ^ĂŶĚƉŽƌĐŝŶĞ'<ɲ ?S2, S5]. 
  
Figure S2. Comparison of tertiary structure for human SK1 and B. anthracis DGK. Top: SK1 co-crystal structure (3VZB 
chain A) with bound Sph (blue surface) and ADP (pink surface) superimposed from its (separate) SK1 co-crystal 
structure (3VZD chain C). Bottom: corresponding view of the B. anthracis putative DGK crystal structure (3T5P chain B) 
colour coded to match the SK1 structure (Ribbon key: see main text, Figure 1). Inspection of the DAGK_cat structures 
collectively reveals a general pattern wherein LBL-1 (cyan) is characterised by helical secondary structure elements 
connected by ĨůĞǆŝďůĞ ůŝŶŬĞƌƐ  ?ĚŝƐŽƌĚĞƌĞĚ ŝŶ ƐĞǀĞƌĂů ŽĨ ƚŚĞ ĐƌǇƐƚĂů ƐƚƌƵĐƚƵƌĞƐ ? ƚŽ ƚŚĞ ĐŽƌĞ ɴ-sandwich. Thus, the B. 
anthracis DGK structures (3S40, 3T5P, 4WRR) exhibit a twin-helix organisation to LBL-1, but, as shown here (bottom), 
with a helix collapsed against the hydrophobic inner surface of the d ĐŽƌĞ ɴ-sandwich, occupying the region 
corresponding to the Sph binding J-channel of SK1. At present it is unclear whether the DGK might act on its lipid 
substrate whilst still membrane embedded or whether it might operate through an extraction-encapsulation 
mechanism similar to that postulated for SK1. In principle, the LBL-1 motif of the B. anthracis DGK might undergo 
conformational reorganisation to provide a more capacious lipid binding pocket in the CTD suitable for the 
encapsulation of a larger DAG substrate.  
  
    
 Figure S3. SK inhibitors with crystallographically-defined binding modes and residue interaction maps. Top row: SKI-II 
(green stick) is shown from the ternary co-crystal structure (3VZD- ?ǁŝƚŚDŐ 笀AW ?S6]. The inhibitor binds deep in 
the J-ĐŚĂŶŶĞů ?ŚǇĚƌŽŐĞŶďŽŶĚŝŶŐƚŽɲ ?- ? ? ?ĂŶĚɲ ?-T196. It lacks a Sph-mimetic head group and the position of the 
Sph-3-OH is taken by a water molecule (W2), also seen in the apo-SK1 structure (3VZB-C). W2 surrogacy provides 
water-bridged conservation of the connectivity between D178 and A339/G342/S168, suggesting that this network is 
an integral structural feature and that SK1 is highly preorganised for substrate binding. A third water (W3) 
approximates to the Sph-1-OH position but is more tightly hydrogen bonded to D81. The looser engagement of D81 by 
Sph (main text, Figure 1) suggests that the substrate is anchored in the J-channel and that some P-loop/T-loop 
movement may occur upon ATP binding to tighten the Sph-1-OH/D81 interaction for deprotonation. Centre row: 
Modification of SKI-II with a Sph-mimetic head group afforded Amgen-1V2, shown here (orange stick) from its SK1 
co-crystal structure (4L02) [S7]. The inhibitors hydroxymethyl group occupies the Sph-3-OH position, obviating a 
requirement for W2 surrogacy; its 2°-hydroxyl engages D81 (close to the W3 position) whilst the piperidinium nitrogen 
adds a salt bridge with D178. Bottom row: PF-543 is shown (yellow stick) from its SK1 co-crystal structure (4V24) [S8]. 
The (hydroxymethyl)pyrrolidine binds with similar interactions to the (hydroxymethyl)piperidine of Amgen-1V2. Head 
group rotation, probably with concomitant W2 occupancy, would place the hydroxymethyl group close to the Sph-1-
OH position, accounting for its known weak substrate character [S9].  
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